Business
AirSculpt operates body-contouring centers providing minimally invasive fat-removal and skin-tightening procedures.
AirSculpt's procedure revenue declined into a loss, while a material weakness, an error correction and a software impairment offset its near-breakeven free cash flow.
The read at a glance✓ Audited against SEC data
- Growth — Revenue declined 15.8%Watch
- Profitability — The net loss widened from $8.018M to $11.667MWatch
- Cash flow — Free cash flow turned positive at $692K from an outflow of $2.657MOK
- Margins — Operating margin contracted 673 bps to -7.61%Watch
- Accounting — Material weakness and corrected financial statementsWatch
- Insiders — 13 purchases and 0 salesOK
Where the revenue comes from
Fiscal 2025, as Airsculpt Technologies, Inc. reports it. History and quarterly detail are in the app.
- Reportable$151.8M
Leadership changes
From Airsculpt Technologies, Inc.'s own filings, the day they're filed.
- Aaron Rollins · chairman of the board · departureeff. 2025-11-04
- Philip Bodie · Chief Accounting Officer · departureeff. 2025-08-01
- Pamela Netzky · director · departureeff. 2024-12-24
Latest filings
- 8-K · Company announcement2026-08-12
- 10-Q · Quarterly report2026-08-10
- 8-K · Company announcement2026-08-10
- 8-K · Company announcement2026-05-14
- 8-K · Company announcement2026-05-08
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Airsculpt Technologies, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.